165 related articles for article (PubMed ID: 32851343)
21.
Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
[TBL] [Abstract][Full Text] [Related]
22. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Enk H; Tytgat GA
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012442. PubMed ID: 31016728
[TBL] [Abstract][Full Text] [Related]
23. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
[TBL] [Abstract][Full Text] [Related]
24. State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma.
Lutskovich D; Meleshko A; Katsin M
Cytotherapy; 2024 May; ():. PubMed ID: 38852096
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
26. The impact of surgical radicality on outcome in childhood neuroblastoma.
von Schweinitz D; Hero B; Berthold F
Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
[TBL] [Abstract][Full Text] [Related]
27. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
[TBL] [Abstract][Full Text] [Related]
28. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
Mora J; Castañeda A; Colombo MC; Gorostegui M; Gomez F; Mañe S; Santa-Maria V; Garraus M; Macias N; Perez-Jaume S; Muñoz O; Muñoz JP; Barber I; Suñol M
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809255
[TBL] [Abstract][Full Text] [Related]
30. Stage 4N neuroblastoma before and during the era of anti-G
Kushner BH; LaQuaglia MP; Cardenas FI; Basu EM; Gerstle JT; Kramer K; Roberts SS; Wolden SL; Cheung NV; Modak S
Int J Cancer; 2023 Dec; 153(12):2019-2031. PubMed ID: 37602920
[TBL] [Abstract][Full Text] [Related]
31. MYCN amplification, TERT rearrangements and ATRX mutations in neuroblastoma: clinicopathological correlates- an Indian perspective.
Kerkar AN; Chinnam D; Verma A; Peters NJ; Kakkar N; Trehan A; Singh M; Gupta K
Virchows Arch; 2023 Oct; 483(4):477-486. PubMed ID: 37460674
[TBL] [Abstract][Full Text] [Related]
32. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Heczey A; Louis CU; Savoldo B; Dakhova O; Durett A; Grilley B; Liu H; Wu MF; Mei Z; Gee A; Mehta B; Zhang H; Mahmood N; Tashiro H; Heslop HE; Dotti G; Rooney CM; Brenner MK
Mol Ther; 2017 Sep; 25(9):2214-2224. PubMed ID: 28602436
[TBL] [Abstract][Full Text] [Related]
33. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
34. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
36. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
37. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
Gorostegui M; Muñoz JP; Perez-Jaume S; Simao-Rafael M; Larrosa C; Garraus M; Salvador N; Lavarino C; Krauel L; Mañe S; Castañeda A; Mora J
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730688
[TBL] [Abstract][Full Text] [Related]
38. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.
Minard V; Hartmann O; Peyroulet MC; Michon J; Coze C; Defachelle AS; Lejars O; Perel Y; Bergeron C; Boutard P; Leverger G; Stephan JL; Thyss A; Chastagner P; Couillault G; Devalck C; Lutz P; Mechinaud F; Millot F; Plantaz D; Rialland X; Rubie H
Br J Cancer; 2000 Oct; 83(8):973-9. PubMed ID: 10993641
[TBL] [Abstract][Full Text] [Related]
39.
Yue ZX; Huang C; Gao C; Xing TY; Liu SG; Li XJ; Zhao Q; Wang XS; Zhao W; Jin M; Ma XL
Cancer Cell Int; 2017; 17():43. PubMed ID: 28367105
[No Abstract] [Full Text] [Related]
40. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
